John A. Bartlett, MD

Related Content

Services

• AIDS Research and Treatment Center (DART)
• Infectious Diseases

Department / Division:
Medicine / Infectious Diseases and International Health

Address:
DUMC 3238
Durham, NC 27710

Appointment Telephone:
919-668-7630

Fax Telephone:
919-479-2948

• MD, University of Virginia, 1981

• Infectious Diseases, Duke University Medical Center, 1982-1984, 1985-1987

Clinical Interests:
General infectious diseases, human immune deficiencies, HIV, AIDS

Research Interests:
My clinical investigation is focused on the pathogenesis and treatment of HIV infection and its complicastions, especially in resource-limited settings.

Key Words: HIV infection, AIDS, treatment strategies, treatment failure, co-infections, resource-limited settings

Representative Publications:
Staszewski S, Hill AM, Bartlett JA, Eron JJ, Katlama C, Johnson J, Sawyer W, McDade H. Reductions in HIV-1 disease progression for zidovudine/lamivudine relative to control treatments: a meta-analysis of controlled trials. AIDS. 11:477-483, 1997. (1997)

Hecht FM, Wheat J, Korzun AH, Hafner R, Skahan KJ, Larsen R, Limjoco MT, Simpson M, Schneider D, Keefer MC, Clark R, Lai KK, Jacobson JM, Squires K, Bartlett JA and Powderly W. Itraconazole maintenance treatment for histoplasmosis in AIDS: A prospective, multicenter trial. Journal of Immune Deficiency Syndromes and Human Retrovirology. 16:100-107, 1997. (1997)

Ferrari G, Berend C, Ottinger J, Dodge R,Bartlett J, Toso J, Moody D, Tartaglia J, Cox W, Paoletti E, Weinhold K. Replication -defective canarypox (ALVAC) vectors effectively activate anti-human immunodeficiemcy virus-1 cytotoxic T lymphocytes present in infected patients: Implications for antigen-specific immunotherapy. Blood, (90) 6; 2406-2416, 1997. (1997)

Bartlett JA, Hullette C. Central nervous system pneumocysostis in the acquired immune deficiency syndrome. Clinical Infectious Diseases. 25:82-85, 1997. (1997)

Bartlett JA, Berry P, Bockman W, Johnson J, Quinn J, Graham S, DeMasi R, Alexander WJ. A placebo controlled trial of ranitidine in patients with early HIV infection. Journal of Infectious Diseases. 177:231-234, 1997. (1997)

Bartlett JA, Wasserman S, Hicks C, Dodge R, Weinhold K, Tacket C, Ketter N, Wittek A, Palker T, Haynes BF and the DATRI 010 Study Group. Safety and immunogenicity of C4V3 polyvalent synthetic peptides in HIV-infected HLA B7 positive subjects with CD4 cells > 500/mm3. Submitted to Journal of Infectious Diseases.

Bartlett JA, Berend C, Ottinger J, Tyler D, Petroni G, Petinelli C, Weinhold KJ. Co-administration of zidovudine and interleukin-2 increases absolute CD4+ cells in subjects with Walter Reed stage 2 HIV infection: Results of ACTG protocol 042. Submitted to Journal of Infectious Diseases.